
David P Breen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10747836/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiative. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	3
2	New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson's disease. Journal of Neurology, 2020, 267, 288-294.	1.8	25
3	Twinkle-associated familial parkinsonism with Lewy pathology. Neurology, 2020, 95, 644-647.	1.5	6
4	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. Parkinsonism and Related Disorders, 2020, 76, 49-53.	1.1	13
5	Cerebrospinal Fluid Cytokines and Neurodegenerationâ€Associated Proteins in Parkinson's Disease. Movement Disorders, 2020, 35, 1062-1066.	2.2	33
6	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. Brain, Behavior, and Immunity, 2020, 87, 473-488.	2.0	58
7	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. Parkinsonism and Related Disorders, 2020, 71, 44-45.	1.1	6
8	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. Parkinsonism and Related Disorders, 2020, 74, 80.	1.1	2
9	Impact of <i>GBA1</i> variants on long-term clinical progression and mortality in incident Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 695-702.	0.9	48
10	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders, 2019, 34, 1839-1850.	2.2	122
11	Genetic risk of Parkinson disease and progression:. Neurology: Genetics, 2019, 5, e348.	0.9	109
12	Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS. American Journal of Human Genetics, 2019, 105, 151-165.	2.6	170
13	The clinical significance of lower limb tremors. Parkinsonism and Related Disorders, 2019, 65, 165-171.	1.1	7
14	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. Parkinsonism and Related Disorders, 2019, 61, 228-230.	1.1	6
15	Functional movement disorders arising after successful deep brain stimulation. Neurology, 2018, 90, 931-932.	1.5	9
16	Infantile-onset hand dystonia with intellectual disability. Neurology, 2018, 90, 333-335.	1.5	3
17	CLIPPERS: A Treatable Cause of Spastic Ataxia. Movement Disorders Clinical Practice, 2018, 5, 212-214.	0.8	1
18	α‧ynuclein strains in multiple system atrophy: A product of their environment?. Movement Disorders, 2018, 33, 1270-1270.	2.2	2

DAVID P BREEN

#	Article	IF	CITATIONS
19	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. Parkinsonism and Related Disorders, 2018, 56, 109-110.	1.1	53
20	Sleepâ€related motor and behavioral disorders: Recent advances and new entities. Movement Disorders, 2018, 33, 1042-1055.	2.2	12
21	Neuroendocrine abnormalities in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 176-185.	0.9	70
22	Stability of mild cognitive impairment in newly diagnosed Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 648-652.	0.9	88
23	Exploiting the aggregation properties of alphaâ€synuclein for diagnostic purposes. Movement Disorders, 2017, 32, 106-106.	2.2	0
24	Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	4.9	131
25	Tracking the course of prodromal Parkinson's disease. Brain, 2017, 140, 259-262.	3.7	5
26	Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. Parkinsonism and Related Disorders, 2017, 36, 63-68.	1.1	50
27	Soft tissue plasmacytomas in multiple myeloma. Lancet, The, 2017, 390, 2083.	6.3	9
28	Anti-collapsin response mediator protein 5 encephalitis masquerading as a low-grade brain tumour. Practical Neurology, 2016, 16, 376-380.	0.5	1
29	Exogenous melatonin for Parkinson's disease: †Waking up' to the need for further trials. Parkinsonism and Related Disorders, 2016, 29, 121-122.	1.1	7
30	Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. Parkinsonism and Related Disorders, 2016, 27, 47-53.	1.1	133
31	<scp>S</scp> erum immune markers and disease progression in an incident <scp>P</scp> arkinson's disease cohort (<scp>ICICLEâ€PD</scp>). Movement Disorders, 2016, 31, 995-1003.	2.2	211
32	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Movement Disorders, 2016, 31, 1062-1066.	2.2	59
33	Toscana virus encephalitis following a holiday in Sicily. Practical Neurology, 2016, 16, 139-141.	0.5	7
34	Confirmation of brainstem death. Practical Neurology, 2016, 16, 129-135.	0.5	8
35	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease?. Journal of Parkinson's Disease, 2015, 5, 743-747.	1.5	17
36	Reversible cerebral vasoconstriction syndrome as a cause of thunderclap headache: a retrospective case series study. American Journal of Emergency Medicine, 2015, 33, 859, e3-859, e6	0.7	4

DAVID P BREEN

#	Article	IF	CITATIONS
37	Quality of Life and Mild Cognitive Impairment in Early Parkinson's Disease: Does Subtype Matter?. Journal of Parkinson's Disease, 2015, 4, 331-336.	1.5	22
38	The Impact of Deep Brain Stimulation on Sleep and Olfactory Function in Parkinson's Disease. The Open Neurology Journal, 2015, 9, 70-72.	0.4	20
39	Sleep and Circadian Rhythm Regulation in Early Parkinson Disease. JAMA Neurology, 2014, 71, 589.	4.5	333
40	Characterizing mild cognitive impairment in incident Parkinson disease. Neurology, 2014, 82, 308-316.	1.5	359
41	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain, 2014, 137, 2743-2758.	3.7	127
42	The Central Clock in Patients With Parkinson Disease—Reply. JAMA Neurology, 2014, 71, 1456.	4.5	4
43	Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet, The, 2014, 383, 1138-1146.	6.3	368
44	Determinants of delayed diagnosis in Parkinson's disease. Journal of Neurology, 2013, 260, 1978-1981.	1.8	65
45	Excessive daytime sleepiness and its risk factors in incident Parkinson's disease: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 233-234.	0.9	47
46	The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 544-551.	0.9	94
47	Addenbrooke's Cognitive Examinationâ€Revised for mild cognitive impairment in Parkinson's disease. Movement Disorders, 2012, 27, 1173-1177.	2.2	38
48	Beware temporal arteritis that does not respond promptly to steriods. Age and Ageing, 2010, 39, 140-140.	0.7	0